Redeye provides a research update on Faron Pharmaceuticals following the company’s recent annual report and clinical progress with lead candidate Bexmarilimab. We make some adjustments to our overall estimates following a revision of our model. Accordingly, as we continue to see a compelling case rooted in an exciting pipeline, we revise our fair value range and raise our base case valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/